Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013150 | 0.88 | P2RX7 (0.46) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL22626216 | 0.85 | P2RX7 (0.39) | P2RX7MAPK1 | |
| SCHEMBL18797411 | 0.71 | MAPK1 (0.38) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL31387354 | 0.70 | P2RX7 (0.62) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL2315023 | 0.69 | P2RX7 (0.52) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL19436674 | 0.69 | MAPK1 (0.37) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL31500557 | 0.69 | P2RX7 (0.47) | P2RX7MAPK1 | |
| SCHEMBL169762 | 0.68 | P2RX7 (1.00) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL422542 | 0.67 | P2RX7 (0.89) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL2313496 | 0.65 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233481-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2025-11-13 | — | — | WO | claimed |
| WO-2025234888-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2025-11-13 | — | — | WO | claimed |
| US-12630549-B2 | Pyrazoleamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4688772-A1 | BIARYL DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12528803-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025233481-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025234888-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2025-11-13 | — | — | WO | disclosed |
| US-7994202-B2 | Bicyclic nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7960392-B2 | Nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2314587-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100029733-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029690-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| WO-2010007943-A1 | NITROGENATED HETEROCYCLIC COMPOUND | 旭化成ファーマ株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
| EP-2097416-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen, Inc (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008076425-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | P2RX7 2849/4885MAPK1 4236/4885LPL 1951/4885 |
| US-20100029733-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PTGER1, EDNRA, NMUR1 | P2RX7 433/4885MAPK1 178/4885LPL 4741/4885 |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | EGLN3, EGLN2, HIF1AN | P2RX7 2843/4885MAPK1 3800/4885LPL 3807/4885 |
| US-20100029690-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PTGER1, PTGS1, PTGER2 | P2RX7 854/4885MAPK1 541/4885LPL 4629/4885 |
| US-12630549-B2 | Pyrazoleamide derivatives | CYP11B2, CYP11B1, ADRA1B | P2RX7 659/4885MAPK1 1392/4885LPL 3216/4885 |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP4A11, CYP11B1, CYP2D6 | P2RX7 2552/4885MAPK1 2061/4885LPL 2316/4885 |
| US-12528803-B2 | Inhibitors of αvβ6 integrin | ITGB2, ITGB6, ITGA2 | P2RX7 1115/4885MAPK1 1903/4885LPL 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.